Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer1Department of Pathology, National University of Ireland, Galway, Clinical Science Institute, Costello Road, Galway, Ireland 2Cancer Research-UK Department of Oncology, Cancer Research-UK Genetic Epidemiology Unit and EPIC, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK 3Department of Oncology, University of Cambridge and Cancer Research-UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK
BMC Cancer 2008, 8:153doi:10.1186/1471-2407-8-153
Additional filesAdditional file 1: Table of 36 studies excluded from the meta-analysis. table summarising the 36 studies excluded from the meta-analysis on the basis of small study size and the provision of insufficient data for the pooled analysis. Format: XLS Size: 33KB Download file This file can be viewed with: Microsoft Excel Viewer Additional file 2: References for 36 studies excluded from meta-analysis. References for the 36 studies summarised in additional file 1 that were excluded from meta-analysis. Format: DOC Size: 33KB Download file This file can be viewed with: Microsoft Word Viewer Additional file 3: Reports examining the association between expression of BCL2 and DFS and/or OS that include over 100 cases of breast cancer. table summarising the 17 reports included for the meta-analysis. Format: DOC Size: 67KB Download file This file can be viewed with: Microsoft Word Viewer Additional file 4: Results of univariate and multivariate analyses for OS and DFS for 17 studies included in the meta-analysis. table summarising the results of univariate and multivariate analysis in 17 reports included for the meta-analysis. Format: DOC Size: 68KB Download file This file can be viewed with: Microsoft Word Viewer |




on Google Scholar







author email
corresponding author email